Literature DB >> 30127930

Upregulation of miR-375 inhibits human liver cancer cell growth by modulating cell proliferation and apoptosis via targeting ErbB2.

Lina Li1, Liping Jia1, Yan Ding2.   

Abstract

microRNAs (miRNA/miRs) are a class of small non-coding RNAs; they serve important biological roles in tumorigenesis through the regulation of oncogene expression, and they may be used for the diagnosis and treatment of human cancer. miR-375 was identified to exhibit abnormal expression levels in a number of types of tumor; however, the biological role of miR-375 in human hepatocellular carcinoma (HCC) remains incompletely characterized. The present study investigated the expression of miR-375 in human HCC tissues and human liver cancer cell lines; results from a reverse transcription quantitative polymerase chain reaction analysis indicated that the expression of miR-375 was significantly decreased in tissues and live cancer cell lines, compared with normal tissues and PHH cells. Additional studies demonstrated that the upregulation of miR-375 inhibited human liver cancer cell growth via regulation of cell apoptosis. It was also revealed that the receptor tyrosine-protein kinase erbB-2 (ErbB2) gene was a direct target gene of miR-375, and that the regulation of ErbB2 was associated with the human liver cancer growth. Therefore, the present study demonstrated that miR-375 was expressed at low levels both in human HCC tissues and cell line, compared with normal tissues and PHH cells, and that the induction of miR-375 expression may regulate human liver cancer cell function through targeting the ErbB2 gene, which may potentially improve the diagnosis and treatment of patients with HCC in the future.

Entities:  

Keywords:  apoptosis; human liver cancer cell; microRNA-375; proliferation; receptor tyrosine-protein kinase erbB-2

Year:  2018        PMID: 30127930      PMCID: PMC6096281          DOI: 10.3892/ol.2018.9011

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

2.  Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2.

Authors:  Ning Zhou; Yanli Qu; Chunlei Xu; Yong Tang
Journal:  Exp Ther Med       Date:  2015-12-08       Impact factor: 2.447

Review 3.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

4.  miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB.

Authors:  Yiping Du; Mingxia Zhu; Xin Zhou; Zebo Huang; Jun Zhu; Jing Xu; Gongming Cheng; Yongqian Shu; Ping Liu; Wei Zhu; Tongshan Wang
Journal:  Tumour Biol       Date:  2015-08-20

5.  miR-375 maintains normal pancreatic alpha- and beta-cell mass.

Authors:  Matthew N Poy; Jean Hausser; Mirko Trajkovski; Matthias Braun; Stephan Collins; Patrik Rorsman; Mihaela Zavolan; Markus Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

6.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.

Authors:  Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

7.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

Authors:  Jinmai Jiang; Yuriy Gusev; Ileana Aderca; Teresa A Mettler; David M Nagorney; Daniel J Brackett; Lewis R Roberts; Thomas D Schmittgen
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

9.  Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development.

Authors:  Wigard P Kloosterman; Anne K Lagendijk; René F Ketting; Jon D Moulton; Ronald H A Plasterk
Journal:  PLoS Biol       Date:  2007-08       Impact factor: 8.029

10.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

View more
  12 in total

1.  MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2.

Authors:  Yanhui Xu; Lei Zhang; Lilong Xia; Xinhai Zhu
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

2.  Human marrow stromal cells secrete microRNA-375-containing exosomes to regulate glioma progression.

Authors:  Sheng-Ze Deng; Min-Fang Lai; You-Ping Li; Chun-Hua Xu; Hao-Ran Zhang; Jian-Guo Kuang
Journal:  Cancer Gene Ther       Date:  2019-02-07       Impact factor: 5.987

3.  CircTUBGCP3 Contributes to the Malignant Progression of Rectal Cancer.

Authors:  Yuanyuan Wang; Hua Wang; Chao Li; Jian Zhang; Zhifen Chu; Pu Liu; Xing Zhang; Xiaosong Gu
Journal:  Dig Dis Sci       Date:  2021-09-13       Impact factor: 3.487

4.  lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging.

Authors:  Liying Zhao; Guohua Lou; Aichun Li; Yanning Liu
Journal:  Mol Med Rep       Date:  2020-05-29       Impact factor: 2.952

5.  The Reciprocal Interaction Between LncRNA CCAT1 and miR-375-3p Contribute to the Downregulation of IRF5 Gene Expression by Solasonine in HepG2 Human Hepatocellular Carcinoma Cells.

Authors:  Zheng Liu; ChangJu Ma; XiaoJuan Tang; Qing Tang; LiJie Lou; Yaya Yu; Fang Zheng; JingJing Wu; Xiao-Bo Yang; Wei Wang; Swei Sunny Hann
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

6.  The Role of miR-375-3p and miR-200b-3p in Gastrointestinal Stromal Tumors.

Authors:  Ugne Gyvyte; Rokas Lukosevicius; Ruta Inciuraite; Greta Streleckiene; Greta Gudoityte; Justina Bekampyte; Serena Valentini; Violeta Salteniene; Paulius Ruzgys; Saulius Satkauskas; Kristina Zviniene; Juozas Kupcinskas; Jurgita Skieceviciene
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

7.  Extracellular Vesicle-Encapsulated MicroRNA-375 from Bone Marrow-Derived Mesenchymal Stem Cells Inhibits Hepatocellular Carcinoma Progression through Regulating HOXB3-Mediated Wnt/β-Catenin Pathway.

Authors:  Zhaoxia Yu; Ju Liu; Qiqi Fan; Jun Yu; Xiaoting Ren; Xiaobin Wang
Journal:  Anal Cell Pathol (Amst)       Date:  2022-01-27       Impact factor: 2.916

8.  Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression.

Authors:  Xiaoyan Chen; Angang Wang
Journal:  Onco Targets Ther       Date:  2019-01-10       Impact factor: 4.147

9.  Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation.

Authors:  Yanming Liu; Yue Cao; Wencan Cai; Liangyin Wu; Pingsen Zhao; Xin-Guang Liu
Journal:  PeerJ       Date:  2020-04-29       Impact factor: 2.984

10.  Overexpression of miR-375 Protects Cardiomyocyte Injury following Hypoxic-Reoxygenation Injury.

Authors:  Md Sayed Ali Sheikh
Journal:  Oxid Med Cell Longev       Date:  2020-01-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.